OmniAb公司经理出售的股票总额超过81 000美元,而生物技术公司的股票仍然在3.67美元左右。 OmniAb executives sold stocks totaling over $81,000, while the biotech firm's stock remains around $3.67.

2月18日, OmniAb的首席执行官出售了13 964股公司股票,每股3.68美元,共计51 387.52美元。 On February 18, OmniAb's CEO sold 13,964 shares of the company's stock at $3.68 each, totaling $51,387.52. 共同创始人Charles S. Berkman也出售了8 215股,价值30 231.20美元。 Co-founder Charles S. Berkman also sold 8,215 shares for $30,231.20. 尽管销售量如此,但这两家公司仍有大量库存。 Despite these sales, both still hold significant stock. OmniAb是一家以抗体发现为重点的生物技术公司,其股票交易额大约为3.67美元。 OmniAb, a biotech firm focusing on antibody discovery, has seen its stock traded around $3.67. 机构投资者一直很活跃,分析师已经发布了“买入”评级,目标价格从8美元至11美元不等。 Institutional investors have been active, and analysts have issued "buy" ratings with target prices from $8 to $11.